Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LEADH: Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization : Liquid Embolic Agent for the Treatment of Chronic subDural Hematoma a Randomized Control Study

NCT05374681 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT05374681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05374681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LEADH: Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization : Liquid Embolic Agent for the Treatment of Chronic subDural Hematoma a Randomized Control Study
Lead sponsor
University Hospital, Brest
Phase
Not applicable
Overall status
Recruiting
Start date
March 28, 2023
Completion date
September 28, 2028
Enrollment
550 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic subdural hematoma